1. Academic Validation
  2. New selective ligands of human cloned melatonin MT1 and MT2 receptors

New selective ligands of human cloned melatonin MT1 and MT2 receptors

  • Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61. doi: 10.1007/s00210-003-0751-2.
Valérie Audinot 1 François Mailliet Chantal Lahaye-Brasseur Anne Bonnaud Aude Le Gall Christophe Amossé Sandra Dromaint Marianne Rodriguez Nadine Nagel Jean-Pierre Galizzi Benoît Malpaux Gérald Guillaumet Daniel Lesieur François Lefoulon Pierre Renard Philippe Delagrange Jean A Boutin
Affiliations

Affiliation

  • 1 Division de Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, 125, Chemin de Ronde, 78290 Croissy-sur-Seine, France.
Abstract

Melatonin has a key role in the circadian rhythm relay to periphery organs. Melatonin exerts its multiple roles mainly through two seven transmembrane domain, G-coupled receptors, namely MT1 or MT2 receptors. A pharmacological characterization of these human cloned melatonin hMT1 and hMT2 receptors stably expressed in HEK-293 or CHO cells is presented using a 2-[125I]-iodo-melatonin binding assay and a [35S]-GTPgammaS functional assay. Both reference compounds and new chemically diverse ligands were evaluated. Binding affinities at each receptor were found to be comparable on either HEK-293 or CHO cell membranes. Novel non-selective or selective hMT1 and hMT2 ligands are described. The [35S]-GTPgammaS functional assay was used to define the functional activity of these compounds which included partial, full agonist and/or antagonist activity. None of the compounds acted as an inverse agonist. We report new types of selective antagonists, such as S 25567 and S 26131 for MT1 and S 24601 for MT2. These studies brought other new molecular tools such as the selective MT1 Agonist, S 24268, as well as the non-selective antagonist, S 22153. Finally, we also discovered S 25150, the most potent Melatonin Receptor Agonist, so far reported in the literature.

Figures